Human genetics, multiple drug classes and experimental retention evidence support a causal role for atherogenic lipoprotein exposure. Remaining gaps concern the best exposure metric, lifetime treatment timing and populations in which lowering does not reduce the measured outcome.
This dated addendum adds selected evidence and tests that could resolve the remaining questions. It does not regrade the archived review.
Each question identifies a limit in the checked evidence. A missing search result alone does not establish a gap in the entire field.
Competing explanation: Particle number, particle type and cholesterol content may diverge while conventional LDL-C remains correlated.
Discriminating test: Prospective discordance analyses and orthogonal instruments with conditional-strength checks; measure apoB, LDL-C, remnants and lipoprotein(a).
Competing explanation: Competing nonatherosclerotic events or irreversible disease may dominate outcomes.
Discriminating test: Mechanism-specific outcome adjudication and disease-stage studies with competing-risk analyses; distinguish null benefit in a population from absence of causal atherogenesis.
Competing explanation: Short clinical trials underestimate cumulative lifelong exposure effects and can miss later harms.
Discriminating test: Extended follow-up and earlier-treatment randomized evidence where feasible, with absolute-risk and adherence measures; do not equate genetic and drug effect sizes.
Competing explanation: Inflammation, other apoB particles, thrombosis and established plaque can contribute independently.
Discriminating test: Factorial or complementary interventions with prespecified lipid and nonlipid pathways, hard events and target engagement.
Electronic publication dates are used where recorded, with issue years shown separately. This is a selected chronology, not a claim of scientific priority or independent replication for every entry.
Simvastatin reduced coronary events and improved survival in established coronary disease.
What it cannot establish: A drug effect is not an isolated manipulation of particle count versus cholesterol content.
Reduced arterial retention affinity lowered atherosclerosis.
What it cannot establish: A model mechanism does not quantify every human risk pathway.
Atorvastatin did not significantly improve the composite primary endpoint.
What it cannot establish: Advanced renal disease and competing pathology bound broad extrapolation.
Lifelong genetically lower LDL was associated with fewer coronary events.
What it cannot establish: Genetic exposure timing and possible pleiotropy differ from starting treatment later.
Adding ezetimibe lowered LDL further and improved cardiovascular outcomes.
What it cannot establish: The achieved exposure changes multiple correlated lipid measures.
PCSK9 inhibition lowered LDL and reduced cardiovascular events.
What it cannot establish: Background therapy, population risk and follow-up duration define scope.
ApoB accounted for much of the modeled lipid–coronary relationship.
What it cannot establish: Correlated traits and conditional instrument strength limit exclusive component attribution.
Bempedoic acid reduced major events in statin-intolerant patients.
What it cannot establish: Benefits and adverse effects remain population- and drug-specific.
Evolocumab reduced first events in high-risk people without previous myocardial infarction or stroke.
What it cannot establish: Atherosclerosis or diabetes eligibility is not unrestricted low-risk primary prevention.
Case-specific Consensus records assisted gap discovery, chronology and targeted paper questions. Shared template wording about an amyloid-specific Deep follow-up is not evidence of a Deep run for this topic; the dated source records establish the actual use and access limits. Primary identifiers, selected abstract passages, correction notices and available primary-body passages were cross-checked. Generated absence cells, duplicate milestones and unsupported access claims were rejected.
Methods table and instrument-strength paragraph: conditional apoB F-statistics of 36 and 66 are present in the primary text, although unavailable in Consensus excerpts. These do not imply every correlated exposure is independently identified.
This focused addendum does not establish 50–70 complete primary Methods/Results examinations per review. Baseline reading receipts and scores retain their original scope.
Selected full-text checks: 1; abstract checks: 8; metadata-only anchors: 0. Complete-paper examinations credited in this update: 0.
New enrichment: HSEF v5.3 causal distinctions. Archived scorecard schema: 5.4; retained as recorded.
VESALIUS-CV has a 2026 issue date and a 2025 electronic publication date. Its high-risk first-event population is narrower than a claim about all primary prevention.
Selected abstract passages checked. Primary record and selected abstract passages checked; no complete-paper appraisal credited.
PMID 12066187 · DOI 10.1038/nature00804
Selected abstract passages checked. Primary record and selected abstract passages checked; no complete-paper appraisal credited.
PMID 16034009 · DOI 10.1056/NEJMoa043545
Selected abstract passages checked. Primary record and selected abstract passages checked; no complete-paper appraisal credited.
Linked notices: Correction (identifier unavailable in this record)
Linked notice presence was checked in the primary record; its scientific impact was not verified in this update.
PMID 16554528 · DOI 10.1056/NEJMoa054013
Selected abstract passages checked. Primary record and selected abstract passages checked; no complete-paper appraisal credited.
PMID 26039521 · DOI 10.1056/NEJMoa1410489
Selected abstract passages checked. Primary record and selected abstract passages checked; no complete-paper appraisal credited.
PMID 28304224 · DOI 10.1056/NEJMoa1615664
Selected abstract passages checked. Primary record and selected abstract passages checked; no complete-paper appraisal credited.
PMID 32203549 · DOI 10.1371/journal.pmed.1003062
Selected full-text passages checked. Methods table and instrument-strength paragraph: conditional apoB F-statistics of 36 and 66 are present in the primary text, although unavailable in Consensus excerpts. These do not imply every correlated exposure is independently identified.
PMID 36876740 · DOI 10.1056/NEJMoa2215024
Selected abstract passages checked. Primary record and selected abstract passages checked; no complete-paper appraisal credited.
PMID 41211925 · DOI 10.1056/NEJMoa2514428
Selected abstract passages checked. Primary record and selected abstract passages checked; no complete-paper appraisal credited.
Read the dated addendum · Video script and storyboard insert · References (RIS) · References (BibTeX)